The European inhalable drug market is anticipated to grow at a CAGR of 3.3% over the forecast period (2020-2026). The key factors that drive the growth of the market include the support by the key players functioning in the market, rising geriatric population, sedentary lifestyles, along with the change in eating habits of the people. The major countries of Europe considered in the report include the UK, France, Germany, Italy, Spain, and the Rest of Europe.

Request a Free Sample of our Europe Inhalable Drugs Market: https://www.omrglobal.com/request-sample/europe-inhalable-drugs-market

The UK is considered a promising market for the European inhalable drug industry. According to Diabetes UK, in 2019, there were almost 3.7 million people who were diagnosed with diabetes in the country, representing 6% of the UK population. This represents 1 in every 16 people with suffer from diabetes. By 2025, it is estimated that five million people are likely to suffer from diabetes in the UK, according to Diabetes UK. This creates demand for inhalable insulin, especially among aged people, and hence creates scope for market growth.
Besides, the key player's contributions are also further driving the European market over the forecast period. F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, Boehringer Ingelheim GmbH, and AstraZeneca Plc are some of the players operating in the market in the region. These players adopt several growth strategies such as product launches, innovations, mergers, and acquisitions in order to thrive in the competitive market. For instance, in February 2017, Boehringer Ingelheim Pharmaceuticals announced that the FDA approved SPIRIVA RESPIMAT, an inhalable spray, for the long-term, once-daily maintenance treatment of asthma in people age 6 and older.

A full Report of Europe Inhalable Drugs Market is Available at: https://www.omrglobal.com/industry-reports/europe-inhalable-drugs-market

Market Coverage

• Market number available for – 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Application and By Route of Administration
• Regions Covered- Europe
• Competitive Landscape- F. Hoffmann-La Roche Ltd., Novartis International AG, AstraZeneca Plc, Boehringer Ingelheim GmbH, and GlaxoSmithKline Plc

Key questions addressed by the report

• What is the market growth rate?
• Which segment/ country dominates the market in the base year?
• Which segment/ country will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID-19 forecast
o Most affected country/ segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Europe Inhalable Drugs Market – Segmentation

By Application

• Respiratory Diseases
• Non- Respiratory Diseases

By Route of Administration

• Nasal
• Mouth

Europe Inhalable Drugs Market – Countries Covered

• UK
• Germany
• France
• Italy
• Spain
• Rest of Europe

Competitive Landscape

• AstraZeneca Plc
• Overview
• AstraZeneca Plc in Europe Landscape
• Recent Developments
• AstraZeneca Plc in Inhalable Drugs
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Johnson & Johnson Services Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Vectura Group Plc
• Verona Pharma plc
• Zambon S.p.A.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/europe-inhalable-drugs-market

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404